EUVIMEDEUVIMED entdecken
Crossref

All‐oral combination of acalabrutinib plus venetoclax approved for adults with CLL or SLL

Leah Lawrence

Cancer · 01.06.2026 · 132 (11)

DOI: 10.1002/cncr.70403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 01.06.2026. Verfasst von Leah Lawrence. Die Arbeit nennt 2 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, phase 3 AMPLIFY trial results show significantly improved progression‐free survival in comparison with standard chemoimmunotherapy for adults with chronic or small lymphocytic leukemia. In addition, a study adds new evidence on use of salvage focal therapy for radio‐recurrent prostate cancer, and stereotactic radiation is linked to fewer symptoms in patients with 5–20 brain metastases.

Zitieren

APA

Lawrence, L. (2026). All‐oral combination of acalabrutinib plus venetoclax approved for adults with CLL or SLL. Cancer, 132(11). https://doi.org/10.1002/cncr.70403

Vancouver

Lawrence L. All‐oral combination of acalabrutinib plus venetoclax approved for adults with CLL or SLL. Cancer. 2026;132(11). doi:10.1002/cncr.70403

BibTeX
@article{Lawrence2026,
  author = {Lawrence, Leah},
  title = {All‐oral combination of acalabrutinib plus venetoclax approved for adults with CLL or SLL},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {11},
  doi = {10.1002/cncr.70403}
}
Kostenlos starten →